配方將是Guardion最近收購的NutriGuard業務線推出的第一種營養產品
設計用於在中國冠狀病毒爆發後所提供免疫支持的配方
聖地亞哥訊：
2020年2月6日– Guardion Health Sciences，Inc。（“ Guardion”或“公司”）（納斯達克股票代碼：GHSI）宣布開發一種獨特的專有配方，以提供免疫支持和抗炎作用針對呼吸道的益處。據信最近起源於中國的冠狀病毒（2019-nCOV）近期爆發導致急性呼吸系統疾病，可能致命。該公司的努力是由其最近收購的NutriGuard業務線帶頭的。 NutriGuard制定了高質量，科學可信，針對特定病情的營養保健品，旨在補充消費者的飲食並幫助預防和管理多種疾病和狀況。
該專有新產品最初被標記為acuMMUNE（商標註冊中），是由Guardion的內部產品和技術設計團隊設計的，並且是Guardion首次以NutriGuard標籤推出的產品。設計acuMMUNE製劑的目的是支持有效的免疫功能-尤其包括干擾素介導的抗病毒機制-同時還減輕過度的肺部炎症，這可能導致嚴重的症狀，甚至因與之相關的嚴重的肺部感染而導致死亡某些病毒感染。儘管acuMMUNE配方旨在為使用者提供免疫支持和抗炎支持以及益處，但尚未使用acuMMUNE或對其進行測試，也無意專門解決冠狀病毒的症狀。
acuMMUNE最初將以膠囊形式提供，並將通過該公司的網站（www.guardionhealth.com和www.nutriguard.com）在美國上市。該公司目前正在安排在美國的合同工廠生產和包裝acuMMUNE，預計該產品將於2020年4月左右開始銷售。該公司預計acuMMUNE也將可供出口。此後不久便進入了各個國際市場。
冠狀病毒已發展成為一種全球流行病，自2019年12月首次被發現以來，在中國已確認20,000例病例，並且對全球經濟的風險正在增加。世界衛生組織（WHO）最近宣布，冠狀病毒爆發是全球性的緊急事件，因為它已經蔓延到中國以外的國家，而且感染病人的人數還在繼續增加。疾病控制與預防中心（CDC）發布了《健康更新》，指出目前尚無疫苗或特定治療方法，並且目前，冠狀病毒患者的醫療服務僅包括輔助治療。
Guardion首席執行官Michael Favish評論說：“我們相信這種靶向產品可以提供及時的免疫應答方案，我們希望它可以為管理冠狀病毒在中國和世界其他地方的影響做出有意義的貢獻。 ” （ Guardion®）
About Guardion Health Sciences, Inc.
Guardion was formed as an ocular health sciences company to develop, formulate, manufacture and distribute condition-specific medical foods supported by evidence-based protocols, with an initial medical food product, Lumega-Z, that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.
About VectorVision®
VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials. VectorVision® is a wholly-owned subsidiary of Guardion.
Guardion has completed development of the proprietary VectorVision® CSV-2000 standardized contrast sensitivity test and recently introduced the commercial product to the marketplace. The CSV-2000 is the only computer-generated vision testing instrument available that will provide the optical marketplace with the Company’s proprietary, industry-standard contrast sensitivity test, along with a full suite of standard vision testing protocols. The proprietary standardization methodology incorporated into the CSV-2000 includes a patented technology known as AcQviz that automatically and constantly measures and adjusts screen luminance to a fixed standard light level for vision testing.
About NutriGuard
NutriGuard formulates high-quality, scientifically-credible nutraceuticals, which are designed to supplement consumers’ diets and assist in the prevention and management of an array of diseases and conditions. NutriGuard uses pharmaceutical standards to establish the safety and efficacy of the products it develops and markets, and also maintains that commitment through rigorous manufacturing and quality assurance programs. Guardion plans to increase NutriGuard’s existing customer base and build on its product platform by making NutriGuard products available to patients directly and through recommendations by their physicians.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and the Company’s ability to successfully develop and commercialize its proprietary products and technologies, including acuMMUNE. acuMMUNE has not been used nor tested, nor is it intended, to specifically address symptoms of the coronavirus. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Porter, LeVay & Rose, Inc.
Michael Porter
Telephone: (212) 564-4700
E-mail: [email protected]
Matthew Abenante
Telephone: (212) 564-4700
E-mail: [email protected]
